Suppr超能文献

正电子发射断层扫描/磁共振成像与正电子发射断层扫描/计算机断层扫描在全身分期中的比较:一项对 1003 例连续检查的单中心观察性研究的结果。

PET/MRI Versus PET/CT for Whole-Body Staging: Results from a Single-Center Observational Study on 1,003 Sequential Examinations.

机构信息

Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, Dusseldorf, Germany

Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

出版信息

J Nucl Med. 2020 Aug;61(8):1131-1136. doi: 10.2967/jnumed.119.233940. Epub 2019 Dec 5.

Abstract

Our purpose was to investigate differences between PET/MRI and PET/CT in lesion detection and classification in oncologic whole-body examinations and to investigate radiation exposure differences between the 2 modalities. In this observational single-center study, 1,003 oncologic examinations (918 patients; mean age, 57.8 ± 14.4 y) were included. Patients underwent PET/CT and subsequent PET/MRI (149.8 ± 49.7 min after tracer administration). Examinations were reviewed by radiologists and nuclear medicine physicians in consensus. Additional findings, characterization of indeterminate findings on PET/CT, and missed findings on PET/MRI, including their clinical relevance and effective dose of both modalities, were investigated. The McNemar test was used to compare lesion detection between the 2 hybrid imaging modalities ( < 0.001, indicating statistical significance). Additional information on PET/MRI was reported for 26.3% (264/1,003) of examinations, compared with PET/CT ( < 0.001). Of these, additional malignant findings were detected in 5.3% (53/1,003), leading to a change in TNM staging in 2.9% (29/1,003) due to PET/MRI. Definite lesion classification of indeterminate PET/CT findings was possible in 11.1% (111/1,003) with PET/MRI. In 2.9% (29/1,003), lesions detected on PET/CT were not visible on PET/MRI. Malignant lesions were missed in 1.2% (12/1,003) on PET/MRI, leading to a change in TNM staging in 0.5% (5/1,003). The estimated mean effective dose for whole-body PET/CT amounted to 17.6 ± 8.7 mSv, in comparison to 3.6 ± 1.4 mSv for PET/MRI, resulting in a potential dose reduction of 79.6% ( < 0.001). PET/MRI facilitates staging comparable to that of PET/CT and improves lesion detectability in selected cancers, potentially helping to promote fast, efficient local and whole-body staging in 1 step, when additional MRI is recommended. Furthermore, younger patients may benefit from the reduced radiation exposure of PET/MRI.

摘要

我们的目的是研究 PET/MRI 和 PET/CT 在肿瘤全身检查中的病灶检测和分类差异,并研究两种方法的辐射暴露差异。在这项观察性单中心研究中,纳入了 1003 例肿瘤检查(918 例患者;平均年龄 57.8 ± 14.4 岁)。患者在示踪剂给药后 149.8 ± 49.7 分钟接受了 PET/CT 和随后的 PET/MRI。检查由放射科医生和核医学医生共同审查。研究了额外的发现、PET/CT 上不确定发现的特征以及 PET/MRI 上的遗漏发现,包括它们的临床相关性和两种方式的有效剂量。采用 McNemar 检验比较两种混合成像方式的病灶检出率(<0.001,表明具有统计学意义)。与 PET/CT 相比,报告了 26.3%(264/1003)检查的 PET/MRI 额外信息(<0.001)。其中,5.3%(53/1003)发现了额外的恶性发现,导致 2.9%(29/1003)因 PET/MRI 而改变 TNM 分期。11.1%(111/1003)的 PET/CT 不确定发现可通过 PET/MRI 进行明确的病灶分类。2.9%(29/1003)的病变在 PET/MRI 上不可见。1.2%(12/1003)的 PET/MRI 上恶性病变漏诊,导致 0.5%(5/1003)的 TNM 分期改变。全身 PET/CT 的估计平均有效剂量为 17.6 ± 8.7 mSv,而 PET/MRI 为 3.6 ± 1.4 mSv,因此潜在的剂量减少了 79.6%(<0.001)。PET/MRI 有助于分期,与 PET/CT 相当,并提高了选定癌症的病灶检出率,当建议进行额外的 MRI 时,可能有助于快速、高效地进行局部和全身分期。此外,年轻患者可能受益于 PET/MRI 辐射暴露的减少。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验